Viewing Study NCT02477670



Ignite Creation Date: 2024-05-06 @ 7:06 AM
Last Modification Date: 2024-10-26 @ 11:45 AM
Study NCT ID: NCT02477670
Status: COMPLETED
Last Update Posted: 2020-09-16
First Post: 2015-06-18

Brief Title: Efficacy Safety and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Sponsor: Avanir Pharmaceuticals
Organization: Avanir Pharmaceuticals

Study Overview

Official Title: A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Sequential Parallel Comparison Design SPCD Study to Assess the Efficacy Safety and Tolerability of AVP-786 Deuterated d6-Dextromethorphan Hydrobromide d6-DMQuinidine Sulfate Q as an Adjunctive Treatment for Patients With Residual Schizophrenia
Status: COMPLETED
Status Verified Date: 2020-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objectives of this 12-week study are to evaluate the efficacy safety and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None